CStone adds trispecific antibody to pipeline with Numab deal

CStone will provide early stage R&D funding in exchange for exclusive, Asian rights to develop and commercialize preclinical trispecific antibody ND021 from Numab. The immunotherapy, which targets

Read the full 279 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE